(VIANEWS) – NEOEN (NEOEN.PA), AIRBUS (AIR.PA), NAVAMEDIC (NAVA.OL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. NEOEN (NEOEN.PA)
48.5% sales growth and 7.39% return on equity
Neoen S.A., an independent renewable energy production company, engages in the development and operation of renewable energy power plants. The company operates through Solar Power, Wind Power, Storage, Farm-Down, Development and Investments, and Eliminations segments. It operates in Argentina, Australia, Canada, Ecuador, the United States, Finland, France, Ireland, Italy, Jamaica, Mexico, Mozambique, Portugal, El Salvador, Sweden, and Zambia. Neoen S.A. was incorporated in 2008 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, NEOEN has a trailing twelve months EPS of €1.13.
PE Ratio
NEOEN has a trailing twelve months price to earnings ratio of 21.52. Meaning, the purchaser of the share is investing €21.52 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.39%.
More news about NEOEN.
2. AIRBUS (AIR.PA)
30.3% sales growth and 35.7% return on equity
Airbus SE engages in the design, manufacture, and delivery of aerospace products, services, and solutions worldwide. It operates through three segments: Airbus, Airbus Helicopters, and Airbus Defence and Space. The Airbus segment develops, manufactures, markets, and sells commercial jet passenger aircraft; freighter aircraft; and regional turboprop aircraft and aircraft components, as well as provides aircraft conversion and related services. The Airbus Helicopters segment engages in the development, manufacture, marketing, and sale of civil and military helicopters; and provision of helicopter related services. The Airbus Defence and Space segment designs, develops, delivers, and supports military aircraft, such as combat, mission, transport, tanker aircraft, and their associated services; a range of civil and defence space systems for telecommunications, earth observations, navigation, science, and orbital systems; and unmanned aerial systems. This segment also offers missile and space launcher systems, as well as services around data processing from platforms, secure communication, and cyber security. The company was formerly known as Airbus Group SE and changed its name to Airbus SE in April 2017. Airbus SE was incorporated in 1998 and is based in Leiden, the Netherlands.
Earnings Per Share
As for profitability, AIRBUS has a trailing twelve months EPS of €5.09.
PE Ratio
AIRBUS has a trailing twelve months price to earnings ratio of 29.61. Meaning, the purchaser of the share is investing €29.61 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 35.7%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is a negative 19.6% and positive 13.9% for the next.
More news about AIRBUS.
3. NAVAMEDIC (NAVA.OL)
20.7% sales growth and 11.97% return on equity
Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Northern Europe. The company's product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic acidemia/propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases and renal diseases, fat metabolism, malnutrition, and ketogenic diet. In addition, the company provides consumer health products consisting of non-prescription drugs and health care products for pain relief, cough and cold, gastro, obesity, women's health, and others primarily through pharmacies and drugstores; specialty pharmaceutical products in various therapeutic areas comprising dermatology, wound care, urology, and obesity; and branded generics, including cardiology products and antibiotics. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was incorporated in 2002 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, NAVAMEDIC has a trailing twelve months EPS of kr1.18.
PE Ratio
NAVAMEDIC has a trailing twelve months price to earnings ratio of 32.2. Meaning, the purchaser of the share is investing kr32.2 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.97%.
Sales Growth
NAVAMEDIC’s sales growth is 19% for the current quarter and 20.7% for the next.
More news about NAVAMEDIC.
4. ORKLA (ORK.OL)
17.8% sales growth and 12.71% return on equity
Orkla ASA engages in branded consumer goods, and industrial and financial investment businesses. The company offers branded products, including frozen pizza, ketchup, soups, sauces, bread toppings, and ready-to-eat meals through grocery channels, as well as food service, convenience stores, and petrol stations. It also provides confectionery, biscuit, and snack products; and develops bran and crispbread products, as well as energy snack meals. In addition, the company offers personal care and cleaning products; dietary supplement, sport nutrition, and weight control products; wound care products and first aid equipment; painting tools; basic and wool garments for men, women, and children; and professional cleaning products. Further, it operates Gymgrossisten, Proteinfabrikken, Bodystore, and Fitnessmarket e-commerce portals for health and sports nutrition products; and restaurants. Additionally, the company supplies margarine and butter blends, bread and cake improvers and mixes, yeast, marzipan, and ice cream ingredients; produces and supplies hydro power to the Nordic power market; and develops and sells real estate properties. It offers its food products under the Grandiosa, TORO, Stabburet, Felix, Paulúns, NATURLI', Abba, Beauvais, Den Gamle Fabrik, Spilva, and Vitana brands; confectionery and snacks under the KiMs, Nidar, Stratos, Sætre, Göteborgs Kex, OLW, Panda, Laima, Selga, Taffel, Kalev, and Nói Síríus brands; health and sports nutrition under e Zalo, Jif, Bliw, Grumme, Blenda, Define, Möller's, Collett, Nutrilett, Maxim, Norgesplaster, and Salvequick brands; and food ingredients under the Odense, Mors Hjemmebakte, KronJäst, Bakkedal, and NATURLI brands. It has operations in Norway, Sweden, Denmark, Finland, Iceland, the Baltics, rest of Europe, and internationally. The company was founded in 1918 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, ORKLA has a trailing twelve months EPS of kr5.37.
PE Ratio
ORKLA has a trailing twelve months price to earnings ratio of 14.16. Meaning, the purchaser of the share is investing kr14.16 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.71%.
Moving Average
ORKLA’s worth is under its 50-day moving average of kr80.90 and under its 200-day moving average of kr79.66.
More news about ORKLA.
5. PERNOD RICARD (RI.PA)
7.9% sales growth and 13.85% return on equity
Pernod Ricard SA produces and sells wines and spirits worldwide. The company offers whiskey, vodka, gin, rum, liqueur and bitters, champagne, tequila and mezcal, and aperitif under the brands 100 Pipers, Aberlour, Absolut, Absolut Elyx, Altos, ARARAT, Augier, Avion, Ballantine's, Becherovka, Beefeater, Blenders Pride, Brancott Estate, Campo Viejo, Ceder's, Chivas, Church Road, Clan Campbell, Del Maguey, George Wyndham, Green Spot, Havana Club, Imperial, Imperial Blue, Italicus, J.P. Wiser's, Jacob's Creek, Jameson, Jefferson's, Kahlúa, Kenwood, KI NO BI, Lillet, Long John, L'Orbe, Lot No. 40, Malfy, Malibu, Martell, Method & Madness, Midleton Very Rare, Minttu, Monkey 47, Mumm, Olmeca, Ostoya, Passport Scotch, Pastis 51, Pernod, Perrier-Jouët, Plymouth Gin, Powers, Rabbit Hole, Ramazzotti, Redbreast, Ricard, Royal Salute, Royal Stag, Scapa, Seagram's Gin, Secret Speyside, Smooth Ambler, Something Special, St Hugo, Stoneleigh, Suze, The Glenlivet, TX, Wyborowa, and Ysios. It also provides non-alcoholic beverages under the brands Ceder's, Suze Tonic 0%, Cinzano Spritz 0%, Pacific, Campo Viejo Sparkling 0%, and Jacob's Creek Unvined. Pernod Ricard SA was founded in 1805 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, PERNOD RICARD has a trailing twelve months EPS of €8.81.
PE Ratio
PERNOD RICARD has a trailing twelve months price to earnings ratio of 17.67. Meaning, the purchaser of the share is investing €17.67 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.85%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 5.9%, now sitting on 12.14B for the twelve trailing months.
Sales Growth
PERNOD RICARD’s sales growth is 7.9% for the present quarter and 7.9% for the next.
Yearly Top and Bottom Value
PERNOD RICARD’s stock is valued at €155.70 at 16:20 EST, way below its 52-week high of €218.00 and way higher than its 52-week low of €140.50.
Volume
Today’s last reported volume for PERNOD RICARD is 160435 which is 62.1% below its average volume of 423405.
More news about PERNOD RICARD.
6. EIFFAGE (FGR.PA)
7.5% sales growth and 19.27% return on equity
Eiffage SA engages in the construction, property development, urban development, civil engineering, metallic construction, roads, energy systems, and concessions businesses in France and internationally. The company operates through Construction, Infrastructure, Energy Systems, Concessions, and Holding Company segments. The Construction segment offers urban development, building design and construction, property development, and maintenance and facilities management services. The Infrastructure segment is involved in undertaking civil engineering, road and rail design and construction, drainage, earthworks, and metallic construction. The Energy Systems segment designs, constructs, integrates, operates, and maintains energy and telecommunication systems and equipment. The Concessions segment constructs and manages concession contracts and public-private partnerships. The company was founded in 1844 and is based in Vélizy-Villacoublay, France.
Earnings Per Share
As for profitability, EIFFAGE has a trailing twelve months EPS of €9.72.
PE Ratio
EIFFAGE has a trailing twelve months price to earnings ratio of 9.91. Meaning, the purchaser of the share is investing €9.91 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.27%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 8.9%, now sitting on 21.74B for the twelve trailing months.
Sales Growth
EIFFAGE’s sales growth is 7.5% for the ongoing quarter and 7.5% for the next.
More news about EIFFAGE.
7. ITERA (ITERA.OL)
7.1% sales growth and 86.07% return on equity
Itera ASA, together with its subsidiaries, designs, develops, and operates digital solutions for companies and organizations in Norway, Denmark, and Slovakia. It offers data, artificial intelligence and analytics, development and architecture, test and quality assurance solutions, as well as cloud and application services. The company delivers projects and services in the strategy and consulting, customer experience, and technology and cloud transformation areas. Itera ASA was founded in 1989 and is based in Oslo, Norway.
Earnings Per Share
As for profitability, ITERA has a trailing twelve months EPS of kr0.76.
PE Ratio
ITERA has a trailing twelve months price to earnings ratio of 14.61. Meaning, the purchaser of the share is investing kr14.61 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 86.07%.
Sales Growth
ITERA’s sales growth is 13.5% for the ongoing quarter and 7.1% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 13.5%, now sitting on 854.94M for the twelve trailing months.
Earnings Before Interest, Taxes, Depreciation, and Amortization
ITERA’s EBITDA is 58.57.
Yearly Top and Bottom Value
ITERA’s stock is valued at kr11.10 at 16:20 EST, way under its 52-week high of kr16.50 and higher than its 52-week low of kr10.50.
More news about ITERA.
